Table 1 Patient characteristics
|  | SS (n = 58) | HS (n = 59) | ES (n = 55) |
|---|---|---|---|
Age, years | 58.5 ± 15.0 | 58.1 ± 15.9 | 60.1 ± 14.4 |
Female, % | 63.8 | 64.4 | 70.9 |
Body weight, kg | 55.9 ± 11.8 | 56.8 ± 10.9 | 54.5 ± 9.9 |
Diagnosis | |||
 RA, % | 8.6 | 6.8 | 7.3 |
 SLE, % | 10.3 | 11.9 | 10.9 |
 PM/DM, % | 19.0 | 37.3 | 29.1 |
 Vasculitis syndrome, % | 44.8 | 25.4 | 30.9 |
 Othersa, % | 17.2 | 18.6 | 21.8 |
Disease duration, months (IQR) | 2 (1–5) | 3 (2–7) | 4 (2–9) |
Comorbidities, % | 72.4 | 79.7 | 78.2 |
 ILD, % | 38.0 | 44.1 | 43.6 |
 Other lung comorbiditiesb, % | 12.1 | 8.5 | 5.5 |
 Hypertension, % | 13.8 | 18.6 | 14.5 |
 Diabetes, % | 6.9 | 5.1 | 14.5 |
 CVDc, % | 3.4 | 5.1 | 5.5 |
 CKD, % | 1.7 | 0 | 0 |
 Malignancies, % | 6.9 | 11.9 | 9.1 |
 Others, % | 41.4 | 42.3 | 36.4 |
Baseline laboratory data | |||
 WBC, /μL (NR, 3300‒8600) | 10401 ± 5359 | 9901 ± 4767 | 9743 ± 5177 |
 Lymphocyte, /μL | 1766 ± 1106 | 1933 ± 1244 | 1656 ± 877 |
 IgG, mg/dL (NR, 861‒1747) | 1676 ± 677 | 1668 ± 679 | 2006 ± 1945 |
Treatment before enrollmentd | |||
 CS, % | 15.5 | 13.3 | 14.5 |
 Dosage of CSe, mg/day (IQR) | 13.8 (5–15) | 8.8 (5–10.6) | 6.8 (5–8.125) |
 ISf, % | 1.7 | 3.2 | 7.3 |
 Biologics, % | 1.7 | 0 | 0 |
Dosage of concomitant CS | |||
 At baseline, mg/kg/day (IQR) | 0.97 (0.89–1.01) | 0.97 (0.81–1.02) | 0.94 (0.75–1.05) |
 At week 24, mg/day (IQR) | 12.5 (10–14.25) | 11 (9–15) | 10 (9–12.5) |
Other immunosuppressive treatment between weeks 0 and 12 | |||
 IV pulsed mPSL, % | 20.6 | 32.2 | 20 |
 IS, % | 70.6 | 67.8 | 81.8 |
 Biologics, % | 1.7 | 3.4 | 1.8 |
Other immunosuppressive treatment between weeks 12 and 24 | |||
 IV pulsed mPSL, % | 1.7 | 3.4 | 0 |
 IS, % | 65.5 | 72.9 | 78.2 |
 Biologics, % | 1.7 | 1.7 | 3.6 |